Pucci B - Search Results

1

Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.

Carbone C, Di Gennaro E, Piro G, Milone MR, Pucci B, Caraglia M, Budillon A. Carbone C, et al. Among authors: pucci b. Amino Acids. 2017 Mar;49(3):517-528. doi: 10.1007/s00726-016-2338-5. Epub 2016 Oct 19. Amino Acids. 2017. PMID: 27761756

2

Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells.

Bianchi L, Bruzzese F, Leone A, Gagliardi A, Puglia M, Di Gennaro E, Rocco M, Gimigliano A, Pucci B, Armini A, Bini L, Budillon A. Bianchi L, et al. Among authors: pucci b. Proteomics. 2011 Sep;11(18):3725-42. doi: 10.1002/pmic.201100092. Proteomics. 2011. PMID: 21761561

3

Evaluation of selenite effects on selenoproteins and cytokinome in human hepatoma cell lines.

Rusolo F, Pucci B, Colonna G, Capone F, Guerriero E, Milone MR, Nazzaro M, Volpe MG, Di Bernardo G, Castello G, Costantini S. Rusolo F, et al. Among authors: pucci b. Molecules. 2013 Feb 26;18(3):2549-62. doi: 10.3390/molecules18032549. Molecules. 2013. PMID: 23442931 Free PMC article.

4

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.

Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S, Capone F, Leone A, Di Gennaro E, Caraglia M, Budillon A. Milone MR, et al. Among authors: pucci b. Cell Death Dis. 2013 May 23;4(5):e641. doi: 10.1038/cddis.2013.165. Cell Death Dis. 2013. PMID: 23703386 Free PMC article.

5

Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.

Bruzzese F, Pucci B, Milone MR, Ciardiello C, Franco R, Chianese MI, Rocco M, Di Gennaro E, Leone A, Luciano A, Arra C, Santini D, Caraglia M, Budillon A. Bruzzese F, et al. Among authors: pucci b. Cell Death Dis. 2013 Oct 24;4(10):e878. doi: 10.1038/cddis.2013.406. Cell Death Dis. 2013. PMID: 24157872 Free PMC article.

6

Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype.

Milone MR, Pucci B, Bifulco K, Iannelli F, Lombardi R, Ciardiello C, Bruzzese F, Carriero MV, Budillon A. Milone MR, et al. Among authors: pucci b. Oncotarget. 2015 Mar 10;6(7):5324-41. doi: 10.18632/oncotarget.2694. Oncotarget. 2015. PMID: 25481874 Free PMC article.

7

Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid.

Bizzarro V, Belvedere R, Milone MR, Pucci B, Lombardi R, Bruzzese F, Popolo A, Parente L, Budillon A, Petrella A. Bizzarro V, et al. Among authors: pucci b. Oncotarget. 2015 Sep 22;6(28):25076-92. doi: 10.18632/oncotarget.4725. Oncotarget. 2015. PMID: 26312765 Free PMC article.

8

The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells.

Colangelo T, Polcaro G, Ziccardi P, Muccillo L, Galgani M, Pucci B, Milone MR, Budillon A, Santopaolo M, Mazzoccoli G, Matarese G, Sabatino L, Colantuoni V. Colangelo T, et al. Among authors: pucci b. Cell Death Dis. 2016 Feb 25;7(2):e2108. doi: 10.1038/cddis.2016.29. Cell Death Dis. 2016. PMID: 26913599 Free PMC article.

9

Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer.

Colangelo T, Polcaro G, Ziccardi P, Pucci B, Muccillo L, Galgani M, Fucci A, Milone MR, Budillon A, Santopaolo M, Votino C, Pancione M, Piepoli A, Mazzoccoli G, Binaschi M, Bigioni M, Maggi CA, Fassan M, Laudanna C, Matarese G, Sabatino L, Colantuoni V. Colangelo T, et al. Among authors: pucci b. Cell Death Dis. 2016 Feb 25;7(2):e2120. doi: 10.1038/cddis.2016.28. Cell Death Dis. 2016. PMID: 26913609 Free PMC article.

10

Biotin-targeted Pluronic(®) P123/F127 mixed micelles delivering niclosamide: A repositioning strategy to treat drug-resistant lung cancer cells.

Russo A, Pellosi DS, Pagliara V, Milone MR, Pucci B, Caetano W, Hioka N, Budillon A, Ungaro F, Russo G, Quaglia F. Russo A, et al. Among authors: pucci b. Int J Pharm. 2016 Sep 10;511(1):127-139. doi: 10.1016/j.ijpharm.2016.06.118. Epub 2016 Jun 29. Int J Pharm. 2016. PMID: 27374195

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179 results

Search Page

Filters